A clinical trial listing update dated August 14, 2026 shows a new Phase 1 study involving IBI3040. The trial, titled "Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants," is registered under identifier NCT07765160.
According to the listing, the study status is "not yet recruiting." The trial is designated as Phase 1, indicating it is in an early stage of the clinical research process. The listed participant populations include healthy participants as well as overweight or obese participants.
No further details on enrollment numbers, specific objectives, or timelines were provided in this update. No results or outcomes have been posted for this trial at this stage, consistent with its not-yet-recruiting status.
This update pertains to IBI3040 and is separate from the general regulatory status of calcitonin, which remains an approved compound. Readers should note that this trial record reflects only the registration details as they currently appear on clinicaltrials.gov.
For additional background on calcitonin, including its approved uses and general profile, readers can refer to the compound overview page.